Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Harvard Medical School
Biotech
Dana-Farber oncologist Anthony Letai tapped to direct NCI
Work led by Letai resulted in the development of AbbVie and Roche’s Venclexta (venetoclax), which was first approved by the FDA in 2016 for leukemia.
Darren Incorvaia
Sep 30, 2025 5:50am
Gut microbiota could hold key to why some cancer therapies fail
May 9, 2023 7:20am
Life Bio gene therapy restores visual function in primates
Apr 25, 2023 10:38am
Chronic pain pathway linked to lung cancer
Sep 1, 2022 9:15am
New heart failure findings open door to personalized therapies
Aug 4, 2022 2:00pm
Easing blood clotting through a new pathway
Jan 11, 2022 7:10am
